These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Vaccination against rubella in Britain: benefits and risks. Freestone DS. Dev Biol Stand; 1979; 43():339-48. PubMed ID: 520680 [Abstract] [Full Text] [Related]
5. Success and failure of a rubella immunization programme. Swartz TA, Porath EB, Hornstein L. Dev Biol Stand; 1979; 43():355-60. PubMed ID: 520682 [Abstract] [Full Text] [Related]
15. Immunity to rubella in women of childbearing age in the United Kingdom. Noah ND, Fowle SE. BMJ; 1988 Nov 19; 297(6659):1301-4. PubMed ID: 3144367 [Abstract] [Full Text] [Related]
16. Rubella in Orkney: seroepidemiology and vaccination. Moffat MA, Heywood SN, Laughton E, Gould JJ, Freestone DS. J Hyg (Lond); 1977 Jun 19; 78(3):419-27. PubMed ID: 266542 [Abstract] [Full Text] [Related]
17. Surveillance of antibody to measles, mumps, and rubella by age. Morgan-Capner P, Wright J, Miller CL, Miller E. BMJ; 1988 Sep 24; 297(6651):770-2. PubMed ID: 3142541 [Abstract] [Full Text] [Related]
18. Risk of chronic arthropathy among women after rubella vaccination. Vaccine Safety Datalink Team. Ray P, Black S, Shinefield H, Dillon A, Schwalbe J, Holmes S, Hadler S, Chen R, Cochi S, Wassilak S. JAMA; 1997 Aug 20; 278(7):551-6. PubMed ID: 9268275 [Abstract] [Full Text] [Related]